TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06492616: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Sponsor: Stemline Therapeutics, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 4220 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT06492616 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06492616 Rescue Dossier →